## Inclusion Criteria

### General Eligibility
- Age ≥18 and ≤70 years at time of informed consent
- Documented diagnosis of systemic lupus erythematosus (SLE), idiopathic inflammatory myositis (IIM), or systemic sclerosis (SSc) per established classification criteria (ACR/EULAR)
- Disease duration ≥6 months from initial diagnosis
- Severe, refractory disease despite prior therapy with ≥2 conventional immunosuppressive agents for ≥3 months each (or documented intolerance), including:
  - For SLE: combination therapy including glucocorticoids plus ≥2 of: hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, belimumab, or anifrolumab
  - For IIM: glucocorticoids plus ≥2 of: methotrexate, azathioprine, mycophenolate mofetil, IVIG, rituximab, or JAK inhibitors
  - For SSc: ≥2 of: mycophenolate mofetil, methotrexate, cyclophosphamide, tocilizumab, nintedanib, or rituximab
- Active, measurable disease at screening despite current therapy:
  - **SLE**: SLEDAI-2K ≥10 with involvement of ≥1 major organ system (renal, hematologic, neurologic, cardiopulmonary, or vasculitic) OR SLEDAI-2K ≥6 with ≥2 BILAG A or ≥3 BILAG B domain scores
  - **IIM**: IMACS core set showing active disease with MMT-8 ≤125/150 AND physician global assessment ≥5/10 AND elevated CK or aldolase >2× ULN OR active extramuscular manifestations (ILD with FVC decline ≥5% within 6 months, arthritis, or skin disease)
  - **SSc**: diffuse cutaneous SSc with mRSS ≥15 and disease duration <5 years OR progressive SSc-ILD (decline in FVC ≥5% or DLCO ≥10% within 12 months) with FVC 45-80% predicted
- ECOG performance status 0-2
- Adequate baseline organ function:
  - ANC ≥1,000/μL
  - Platelet count ≥75,000/μL
  - Hemoglobin ≥8.5 g/dL (transfusion permitted if due to disease-related anemia)
  - Absolute lymphocyte count ≥300/μL
  - Serum creatinine ≤2.5 mg/dL AND eGFR ≥30 mL/min/1.73m²
  - Total bilirubin ≤2.5 mg/dL (≤3.5 mg/dL if Gilbert's syndrome or hemolysis)
  - AST and ALT ≤5× ULN
  - LVEF ≥45% by echocardiogram or MUGA
  - Oxygen saturation ≥92% on room air or baseline supplemental oxygen
- Negative serum or urine pregnancy test within 7 days of enrollment for females of childbearing potential
- Highly effective contraception (failure rate <1% per year) for all participants with reproductive potential from screening through 12 months post-CAR T infusion
- Able to provide written informed consent and comply with protocol requirements
- Willing to remain within 2 hours of treatment center for 4 weeks post-infusion

### Disease-Specific Inclusion Criteria

#### SLE
- Fulfills ACR/EULAR 2019 classification criteria (≥10 points with positive ANA)
- Major organ involvement OR glucocorticoid dependence (prednisone ≥10 mg/day or equivalent for ≥3 months) with inability to taper
- **Lupus nephritis cohort**: biopsy-proven Class III, IV, or V within 24 months OR active Class III/IV disease with UPCR ≥1.0 g/g despite standard therapy
- **Neuropsychiatric lupus cohort**: CNS involvement confirmed by imaging, CSF analysis, or neurological assessment attributable to SLE
- **Hematologic cohort**: autoimmune cytopenias (AIHA, ITP, or TTP) requiring chronic treatment or recurrent episodes

#### Idiopathic Inflammatory Myositis
- Fulfills ACR/EULAR 2017 classification criteria for definite or probable IIM
- Subtypes eligible: dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, anti-synthetase syndrome, or overlap myositis
- Objective muscle weakness (MMT-8 ≤125/150) OR significant extramuscular manifestations (progressive ILD, severe cutaneous disease, refractory arthritis)
- Elevated muscle enzymes (CK, aldolase, AST, ALT, or LDH) OR MRI evidence of active myositis OR muscle biopsy showing inflammatory infiltrates within 12 months

#### Systemic Sclerosis
- Fulfills ACR/EULAR 2013 classification criteria (≥9 points)
- **Diffuse cutaneous SSc cohort**: dcSSc with skin involvement proximal to elbows/knees, mRSS ≥15, and disease duration <5 years from first non-Raynaud symptom
- **SSc-ILD cohort**: progressive fibrosing ILD with HRCT evidence of fibrosis involving ≥10% lung volume AND documented progression (FVC decline ≥5% or DLCO decline ≥10% within 12 months) AND FVC 45-80% predicted
- Positive ANA or SSc-specific autoantibodies (anti-topoisomerase I, anti-RNA polymerase III, or anti-centromere)

## Exclusion Criteria

### General Exclusions
- Prior allogeneic hematopoietic stem cell or solid organ transplantation
- Prior autologous hematopoietic stem cell transplant within 12 months
- Prior CD19-targeted therapy (CAR T-cell therapy, bispecific antibody, or antibody-drug conjugate)
- Prior CD20-targeted therapy within 6 months OR persistent B-cell depletion (CD19+ B cells <5% of lymphocytes or absolute CD19+ count <10 cells/μL)
- Active or inadequately treated infection:
  - Positive HIV-1 or HIV-2 serology
  - Active or chronic hepatitis B (HBsAg positive) or hepatitis C (HCV RNA detectable)
  - Active or untreated latent tuberculosis (positive QuantiFERON or T-SPOT without completed treatment)
  - Active systemic infection requiring IV antimicrobials within 72 hours of screening
  - History of severe/recurrent *Pneumocystis jirovecii* pneumonia or other severe opportunistic infections
- Active or history of CNS disorder that could confound safety assessment:
  - Uncontrolled seizure disorder (seizure within 6 months)
  - Cerebrovascular accident or intracranial hemorrhage within 6 months
  - Primary CNS malignancy or CNS metastases
  - Demyelinating disease (multiple sclerosis, transverse myelitis)
- Active malignancy or history of malignancy within 3 years, except:
  - Adequately treated basal or squamous cell skin cancer
  - Carcinoma in situ of cervix, breast, or bladder
  - Low-risk prostate cancer on active surveillance
  - Other malignancy with no evidence of disease for ≥3 years
- Significant cardiovascular disease:
  - NYHA Class III-IV heart failure
  - Acute coronary syndrome or myocardial infarction within 6 months
  - Unstable angina or clinically significant arrhythmia requiring treatment
  - Prolonged QTc >480 msec
  - Cardiac amyloidosis
- Severe pulmonary compromise:
  - **Non-SSc participants**: FVC <50% predicted or DLCO <40% predicted
  - **SSc participants**: FVC <45% predicted AND DLCO <30% predicted
  - Oxygen requirement >4 L/min at rest (unless baseline for SSc-ILD)
  - Moderate-to-severe pulmonary arterial hypertension (mean PAP >35 mmHg on right heart catheterization) with NYHA Class III-IV symptoms
- Uncontrolled systemic disease:
  - Uncontrolled diabetes mellitus (HbA1c >10%)
  - Uncontrolled hypertension (SBP >180 or DBP >110 mmHg despite treatment)
  - Uncontrolled thyroid disease
- Known hypersensitivity to murine proteins, immunoglobulins, or any CAR T product component (including DMSO, albumin)
- Concurrent additional autoimmune disease requiring systemic immunosuppression beyond the study indication (excluding stable autoimmune thyroid disease on replacement therapy)
- Pregnancy or breastfeeding
- History of severe allergic reactions requiring hospitalization or associated with anaphylaxis
- Any condition that, in investigator's opinion, makes participant unsuitable for study participation

### Medication and Treatment Exclusions
- **Lymphocyte-depleting agents**:
  - Alemtuzumab, anti-thymocyte globulin: within 12 months
  - Rituximab or other anti-CD20 therapy: within 6 months or until B-cell reconstitution
- **Cytotoxic agents**: cyclophosphamide within 3 months
- **Biologics**:
  - Belimumab: within 4 months or 5 half-lives
  - Anifrolumab: within 4 months or 5 half-lives
  - Tocilizumab: within 8 weeks or 5 half-lives
  - Anti-TNF agents: within 8 weeks or 5 half-lives
  - Abatacept: within 8 weeks or 5 half-lives
  - JAK inhibitors: within 4 weeks or 5 half-lives
  - Other investigational biologics: within 3 months or 5 half-lives
- Systemic corticosteroids >20 mg/day prednisone equivalent (stable doses ≤20 mg/day permitted; pulse therapy permitted as bridging)
- IVIG or plasmapheresis within 4 weeks (unless used as protocol-specified bridging therapy)
- Live or live-attenuated vaccines within 6 weeks
- Any investigational agent within 30 days or 5 half-lives (whichever longer)
- CNS-penetrating immunosuppressants (e.g., high-dose methotrexate) within 3 months

### Disease-Specific Exclusions

#### SLE
- Active Class I, II, or VI lupus nephritis as sole manifestation
- Scleroderma renal crisis within 12 months
- Catastrophic antiphospholipid syndrome within 6 months
- Thrombotic microangiopathy requiring plasmapheresis within 30 days
- Drug-induced lupus

#### Idiopathic Inflammatory Myositis
- Inclusion body myositis (IBM)
- Active paraneoplastic myositis with known malignancy requiring treatment
- Severe oropharyngeal dysphagia with chronic aspiration requiring feeding tube
- Muscular dystrophy or other hereditary myopathy as primary diagnosis
- Severe rhabdomyolysis (CK >20,000 U/L) within 30 days

#### Systemic Sclerosis
- Scleroderma renal crisis within 12 months
- Limited cutaneous SSc without progressive ILD
- Severe gastrointestinal dysmotility requiring total parenteral nutrition
- Severe gastroparesis with recurrent hospitalizations
- Bowel pseudo-obstruction or documented small bowel bacterial overgrowth requiring chronic antibiotics
- Severe malabsorption syndrome
- Combined pulmonary fibrosis and pulmonary hypertension with both FVC <45% and mean PAP >35 mmHg

### Laboratory Exclusions
- Positive blood culture or evidence of sepsis within 72 hours of apheresis or lymphodepletion
- Active hemolysis causing hemoglobin instability (except controlled autoimmune hemolytic anemia in SLE cohort)
- Severe cytopenias not attributable to autoimmune disease:
  - ANC <500/μL without evidence of autoimmune neutropenia
  - Platelets <50,000/μL without evidence of ITP
- Serum ferritin >10,000 ng/mL suggestive of hemophagocytic lymphohistiocytosis
- Evidence of disseminated intravascular coagulation (DIC)

## Special Considerations

### Permitted Bridging Therapy
Permitted during CAR T manufacturing period (after apheresis, before infusion) to control life-threatening disease:
- High-dose corticosteroid pulse therapy (methylprednisolone ≤1 g/day × 3-5 days)
- IVIG (maximum 2 g/kg per month, last dose ≥14 days before lymphodepletion)
- Plasmapheresis or plasma exchange (last session ≥7 days before lymphodepletion)
- Continuation of baseline immunosuppression at stable or reduced doses

### Required Washout Periods Prior to Lymphodepletion
- Rituximab or anti-CD20: documented B-cell recovery (CD19+ ≥5% or ≥10 cells/μL) OR minimum 6 months, whichever longer
- Cyclophosphamide: 4 weeks
- Methotrexate, azathioprine, mycophenolate: may continue through apheresis but hold during lymphodepletion and infusion period
- Calcineurin inhibitors: may continue at reduced dose
- Hydroxychloroquine: may continue throughout

### CNS Prophylaxis
- Required for all participants with history of CNS involvement
- Intrathecal chemotherapy prophylaxis not required but may be considered for high-risk CNS lupus